Researchers reported first human outcomes for STEM-PD, a Phase 1/2 open-label trial of cryopreserved, off-the-shelf dopaminergic progenitor cells derived from human embryonic stem cells for Parkinson’s disease. In Nature Medicine, the study described eight participants treated in Lund, Sweden with no serious safety signals linked to the transplant during the first year of follow-up. The results support continued clinical development toward larger cohorts, reinforcing stem-cell approaches that aim to restore dopaminergic circuitry rather than manage symptoms alone.